Access to Medicines

SC Project Launch, November 2018

Title:                       Breakfast Meeting for Ambassadors of the Group of 77 and China

                                Launch of Project: A Public Health Approach to Intellectual Property Rights

Date and Time:      9 November 2018, 9-10  AM

Venue:                    Intercontinental Hotel, Room Méditerranée – Benelux, First Floor

Organizers:           South Centre 

(more…)

Policy Brief 54, October 2018

The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment

In late 2013, a new Hepatitis C treatment called direct-acting antivirals (DAAs) was introduced in the market at unaffordable prices. The eradication of the disease is possible if medicines can be purchased at AFFORDABLE prices within health budgets. IF THIS IS NOT THE CASE, governments should consider the use of the TRIPS flexibilities to facilitate access to the treatment.

(more…)

SC WTO Public Forum Event, 2 October 2018

Title:                             Intellectual Property and Health: The Use of TRIPS Flexibilities to Achieve                                                    SDGs

Date and Time:            2 October 2018, 11:30-13:00

Venue:                          Room S1, The World Trade Organization (WTO), Geneva

Organizer:                   The South Centre

(more…)

Announcement, September 2018

New project to scale up access to medicines 

The South Centre is pleased to announce that it is scaling up its services to developing country governments in the area of intellectual property rights and public health, thanks to the support of Unitaid. The project “Expanding the use of TRIPS flexibilities to promote affordable access to medicines” will allow the South Centre to roll out a number of training activities at regional and national level and a global advisory service on the use of TRIPS flexibilities for public health.

(more…)

Statement, September 2018

South Centre Statement for the Informal Consultation on the Roadmap on Access to Medicines

The draft roadmap is an important work in progress that needs to be further detailed with clear deliverables and timelines. The roadmap will need to ensure complementarity of its work and the implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPOA).

(more…)

Policy Brief 50, August 2018

The International Debate on Generic Medicines of Biological Origin

The debate on generic medicines is not new. What makes it different today is that attacks levelled against biological generic products are couched in even more “technical” and abstruse language. The high price of biological drugs stems mainly from the introduction of barriers to the entry of generics into the market. In any debate on the feasibility of producing biological generic products identical to the ‘original’ ones, it should be made clear that what are at stake are not identical products but therapeutic equivalents.

(more…)

SC Side Event to the WHA71, 25 May 2018

Title:                 Side Event to the 71st World Health Assembly, on Access to Medicines: Overcoming Obstacles created by monopolies – Essential to UHC and the 2030 Agenda

Date:                 25 May 2018

Venue:              Room VIII, Palais des Nations, Geneva

Organizers:     Missions of Brazil, India, Morocco, Senegal, and Thailand, with the support of the South Centre

(more…)

SC Consultations with the IACG Subgroup 4, 8 May 2018

Title:                 Consultations with the United Nations Interagency Coordination Group on Antimicrobial Resistance (IACG) Subgroup 4 on Innovation and Access

Date:                 8 May 2018

Venue:              The South Centre, Geneva

Organizers:     The South Centre, Third World Network and ReAct

(more…)

Policy Brief 49, July 2018

Major Outcomes of the 71st Session of the World Health Assembly of WHO

The 71st session of the World Health Assembly (WHA) of the World Health Organization (WHO) took place from 21 to 26 May 2018 in Geneva, Switzerland. The Assembly adopted several decisions and resolutions including the adoption of the General Programme of Work (GPW) of WHO for the period 2019-2023, as well as decisions on addressing access to medicines and vaccines and their global shortage, and the recommendations of an overall programme review of the WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (GSPA-PHI).   (more…)


0

Your Cart